Exagen's Best Quarter Ever, Priced Like a Broken One
A record Q3, a reiterated guide, and a stock 38% off its September high — because almost none of the growth came from volume
XGN · Earnings Call · 2026-11-10
A record quarter the tape refuses to pay for
By management's own arithmetic, Exagen just posted its best third quarter in company history: $18.4 million of revenue, up 7%; a trailing-twelve-month average selling price of $451, a new record; Pharma Services revenue up roughly 85% year-to-date to $2.2 million; and a reiterated full-year guide of $72–75 million. The CEO called it “the best third quarter in company history” — John Aballi, President and Chief Executive Officer · 2026-11-10. The stock, meanwhile, sits 38% below its September 22 peak of $8.74 and 81% below the 2019 high — and it fell that 38% in three weeks, into the print. That gap is the story, and it is not mysterious once you decompose the growth. AVISE CTD revenue was $16.4 million in Q3 versus $17.7 million in Q2. AVISE CTD volume grew 2%, which the CEO himself described as "just above last year's test volume." The quarter's revenue growth came from price and from Pharma, not from more tests. CFO Jeff Black was blunt about the comp: “it really has to do with the year-over-year comps” — Jeffrey Black, Chief Financial Officer · 2026-11-10 — 2025 saw a step-up in average quarterly volume that made for a harder lap. This is a company that grew revenue 16% year-over-year and 15% quarter-over-quarter in its most recent filed quarter (Total Revenue), and is now guiding to a 7% quarter. Analyst Kyle Mikson asked the obvious question — what returns the company to double digits? — and the CEO's answer was the pipeline, not the base business.What Exagen quietly stopped selling
The keyword trail across quarters is unusually revealing here. Last quarter, revenue cycle management was the single highest-rated theme in Exagen's call — the engine behind fourteen straight quarters of ASP gains, ALJ appeal wins, and the collection of aged claims. This quarter it does not appear in the top thirty at all. Neither does accrual rate. In their place: Pharma Services at the top, then ordering physicians, volume growth, commercial investment, myositis offering, podium presentations, Autoimmune Platform, and Exagen Forward. That is a narrative re-rating in real time — from a self-help reimbursement story to a platform-and-pipeline story. The RCM machine hasn't stopped working (ASP still rose $10 year-over-year, and >360-day collections hit about $800,000 in the quarter), but it is no longer the pitch. What management emphasizes instead is the framing of a company moving “from a single product company into an autoimmune platform” — John Aballi, President and Chief Executive Officer · 2026-11-10. The ASP narrative is also, notably, old. Prior calls have used the same eleven-word construction — thirteen consecutive quarters of ASP improvement last August, fourteen now. That is genuinely a record, and also boilerplate.Two things that are actually new
The first is PAMA. For years the reimbursement question was a local coverage determination out of MolDX. This quarter, for the first time, PAMA pricing entered the conversation, and the CEO quantified it: “we do expect some slight headwinds overall in a blended rate. We're talking low single-digit impact if it were to be realized fully.” — John Aballi, President and Chief Executive Officer · 2026-11-10 Exagen's proprietary PLA code survived at a steady $840, but the generic CPT codes it also bills are set by national lab medians and are exposed. Note the arithmetic tension hiding in that same answer: the long-standing ASP target was framed as "at least 50% of Medicare," or roughly $600–$650 — a number that only makes sense against the $1,299 clinical lab fee schedule cited on prior calls, not against an $840 PLA rate whose half is $420, below today's $451 ASP. The Medicare rate anchor has quietly moved, and with it the credibility of the "half of Medicare" math. The second new thing is stranger and more interesting: Exagen bought an AI-enabled workflow optimization platform for rheumatology practices, booking a roughly $600,000 in-process R&D charge. The CEO was candid that “this was somewhat opportunistic” — John Aballi, President and Chief Executive Officer · 2026-11-10 — technology out of Israel that a handful of its own customers already used. Strategically it is a bid to get software platform presence inside clinics where a rep cannot visit 150 physicians a week, and a first step away from the single product label. It is also, so far, a $600,000 charge against a company that just printed a $1.9 million adjusted EBITDA loss.The balance sheet and the bet
Exagen ended Q3 with just over $28 million of cash after raising about $6.5 million through its ATM, then drew $5 million from an expiring Perceptive tranche for roughly $33 million pro forma. That is real runway, funded partly by dilution — and it lands on a balance sheet where Liabilities to Assets has climbed from the mid-20s in 2021 to 76.5%, and where effective net cash was barely $1 million at the last filing (Effective Net Cash). The one genuinely improving credit metric is Receivables to Revenue, down 21 points year-over-year, which is the cash-collection story showing up in the accounts. The bull case collapses to a single date and a single product. Myositis — the number one request from Exagen's own rheumatologists, per the CEO — launches in early 2027 as a 17-marker, quantitative panel with a one-week turnaround. The differentiation is speed and titers:That lands into a genuine autoimmune biologics wave — argenx's Phase III IMNM data came up in Q&A, and the global keyword tape is crowded with the same immunology vocabulary (ACR20 response, paid drug, late-stage development) across peers like Immunovant and Roivant. Diagnostics tend to ride drug approvals with a lag. The $80 million revenue / 60% gross margin breakeven framework is unchanged, and gross margin at 61.3% in the last filed quarter (Gross Margin) says the cost side is already doing its job. At 1.6x revenue, the market is paying almost nothing for that optionality. So the real question isn't whether Q3 was a record. It's whether a company whose growth just decelerated to 7%, whose reimbursement lever is facing its first genuine policy headwind, and whose next act doesn't ship until 2027, deserves to be re-rated on a December 15 webcast. The tape has already answered once.we expect to be able to turn our testing around within a week, which is really critical for the field and current alternatives are in the 4 to 6-week, some even extending to the 8-week time frame.